NASDAQ
16.05USD
-0.05 (-0.31%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
238.4M
P/E
—
EPS
—
Beta
0.00
52W range
12.95-38.41
Day range
15.53–17.80
Open
16.41
Prev close
16.10
Volume
186.6K
Avg volume
180.9K
Dividend
0.00
IPO
2026-08-12
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Vogenx Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VOGX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
